- Home
- THAR vs SLXN Comparison
THAR vs SLXN Comparison
Compare THAR & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- SLXN
- Stock Information
- Founded
- THAR 2017
- SLXN 2008
- Country
- THAR United States
- SLXN Israel
- Employees
- THAR N/A
- SLXN N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- THAR Health Care
- SLXN
- Exchange
- THAR Nasdaq
- SLXN NYSE
- Market Cap
- THAR 4.0M
- SLXN 4.3M
- IPO Year
- THAR 2022
- SLXN N/A
- Fundamental
- Price
- THAR $1.90
- SLXN $0.84
- Analyst Decision
- THAR Strong Buy
- SLXN Strong Buy
- Analyst Count
- THAR 1
- SLXN 1
- Target Price
- THAR $17.00
- SLXN $9.00
- AVG Volume (30 Days)
- THAR 20.9K
- SLXN 31.1M
- Earning Date
- THAR 11-07-2024
- SLXN 03-04-2025
- Dividend Yield
- THAR N/A
- SLXN N/A
- EPS Growth
- THAR N/A
- SLXN N/A
- EPS
- THAR N/A
- SLXN N/A
- Revenue
- THAR N/A
- SLXN N/A
- Revenue This Year
- THAR N/A
- SLXN N/A
- Revenue Next Year
- THAR N/A
- SLXN N/A
- P/E Ratio
- THAR N/A
- SLXN N/A
- Revenue Growth
- THAR N/A
- SLXN N/A
- 52 Week Low
- THAR $1.84
- SLXN $0.21
- 52 Week High
- THAR $7.46
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- THAR 43.41
- SLXN N/A
- Support Level
- THAR $1.86
- SLXN N/A
- Resistance Level
- THAR $1.95
- SLXN N/A
- Average True Range (ATR)
- THAR 0.07
- SLXN 0.00
- MACD
- THAR -0.00
- SLXN 0.00
- Stochastic Oscillator
- THAR 16.33
- SLXN 0.00
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.